Priority setting for pharmaceuticals the use of health economic evidence by reimbursement and clinical guidance committees

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European journal of health economics
1. Verfasser: Anell, Anders (VerfasserIn)
Format: UnknownFormat
Sprache:eng
Veröffentlicht: 2004
Schlagworte:
Arzneimittel > Rückzahlung > Gesundheitsökonomik > Australien > Kanada > Finnland > Frankreich > Großbritannien > Aufsatz in Zeitschrift
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Titel Jahr Verfasser
Low risk, high reward? : repeated competitive biddings with multiple winners in health care 2020 Pitkänen, Visa
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France 2020 Tremblay, Gabriel
How does the integration of collaborative care elements in a gatekeeping system affect the costs for mental health care in Germany? 2020 Engels, Alexander
A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland 2020 Lamrock, Felicity
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations 2020 Westerink, Lotte
The effect of time to death on health care expenditures : taking into account the endogeneity and right censoring of time to death 2020 Kolodziejczyk, Christophe
Lifetime cost of unilateral cochlear implants in adults : a Monte Carlo simulation 2020 Thum, Christin
Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening 2020 Thomas, Rebecca L.
Patterns of care and cost profiles of women with breast cancer in Italy : EPICOST study based on real world data 2020 Francisci, Silvia
Measuring intangible cost-of-morbidity due to substance dependence : implications of using alternative preference-based instruments 2020 Casal Rodríguez, Bruno
Predictors of negotiated prices for new drugs in Germany 2020 Gandjour, Afschin
Should health technology assessment be more patient centric? : If so, how? 2020 Drummond, Michael
Investigating the geographic disparity in quality of care : the case of hospital readmission after acute myocardial infarction in Italy 2020 Wang, Yuxi
The impact of the great economic crisis on mental health care in Italy 2020 Wang, Yuxi
Costs and benefits of interventions aimed at major infectious disease threats : lessons from the literature 2020 Kellerborg, Klas
Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany 2020 Basic, Edin
No gain in pain : psychological well-being, participation, and wages in the BHPS 2020 Lagomarsino, Elena
Trends in rates of orthopedic surgery in Germany : the good, the bad, and the ugly 2020 Gandjour, Afschin
Are quality-adjusted medical prices declining for chronic disease? : evidence from diabetes care in four health systems 2020 Eggleston, Karen
Is the whole larger than the sum of its parts? : impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials 2020 Michalowsky, Bernhard
Alle Artikel auflisten